Fulgent Genetics launched at-home neutralizing antibody test for COVID-19
On Oct. 27, 2021, Fulgent Genetics announced that it had launched an antibody test for COVID-19 which specifically…
BioNTech planned to initiate construction of an mRNA vaccine manufacturing facility in Africa in mid-2022
On Oct. 26, 2021, BioNTech announce that the Company planned to initiate the construction of the first state-of-the-art…
FDA Advisory Committee votes in favor of granting EUA for Pfizer-BioNTech Covid-19 vaccine in children 5 to <12 years
On Oct. 26, 2021, Pfizer and BioNTech announced that the U.S. Food and Drug Administrationﾒs (FDA) Vaccines and…
Vaxart dosed first subject in phase II COVID-19 oral tablet vaccine clinical trial
On Oct. 26, 2021, Vaxart announced that it has dosed the first subject in its Phase II COVID-19…
Biotechnology | Diagnostics | Disease | Oncology | Vaccine | Women's Health
Anixa Biosciences announced patient dosing of investigational vaccine candidate in first-of-its-kind preventative breast cancer vaccine study
On Oct. 26, 2021, Anixa Biosciences announced that, in conjunction with its partner, Cleveland Clinic, it had commenced…
Moderna announced MOU to supply up to 110 million doses of Its COVID-19 vaccine to the African Union
On Oct. 26, 2021, Moderna announced a new Memorandum of Understanding (MoU) to make up to 110 million…
Moderna announced Swissmedic authorized booster dose of Moderna’s COVID-19 vaccine
On Oct. 26, 2021, Moderna announced that Swissmedic had authorized a booster dose of Spikevax, the Company’s vaccine…
Axcella Therapeutics launched clinical program to develop treatment for patients with long COVID
On Oct. 26, 2021, Axcella Therapeutics announced a new clinical program to investigate AXA1125 as a potential treatment…
Merck and Ridgeback initiated rolling review by EMA for Molnupiravir, investigational oral antiviral medicine, for treatment of COVID-19
On Oct. 25, 2021, Merck and Ridgeback Biotherapeutics announced the European Medicines Agency (EMA) had initiated a rolling…
European Commission selected Humanigenﾒs lenzilumab as one of the 10 most promising treatments for COVID-19
On Oct. 25, 2021, Humanigen announced the European Commission had identified lenzilumab as one of the ﾓ10 most…
Moderna announced positive top line data from phase 2/3 study of COVID-19 vaccine in children 6 to 11 years of age
On Oct. 25, 2021, Moderna announced positive interim data from the Phase 2/3 study, called the KidCOVE study,…
Moderna announced EMA’s CHMP recommended booster dose of Moderna’s COVID-19 vaccine in the European Union
On Oct. 25, 2021, Moderna announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…
COVID-19 infection presents greater risk of causing very rare neurological events than vaccines
On Oct. 25, 2021, scientists at Oxford University reported that Infection with COVID-19 carried a much higher risk…
The Department of Veterans Affairs expanded mandate for COVID-19 vaccines among VHA employees
On Oct. 22, 2021, the U.S. Department of Veterans Affairs (VA) announced that it had begun offering Moderna…
HHS invested over $560 million to bolster product manufacturing to increase supply, availability of COVID-19 tests
On Oct. 22, 2021, the Department of Health and Human Services (HHS), announced that it had invested more…
The U.S. CDC reported two new variant Influenza (Flu) virus infections
On Oct. 22, 2021, the U.S. Centers for Disease Control and Prevention (CDC) reported two new U.S. human…
COVID-19 booster increased antibody responses, was protective in rhesus macaques
On Oct. 21, 2021, the National Institutes of Health announced that a booster dose of the mRNA-1273 COVID-19…
Ligand and CR Double-Crane entered agreement to develop oral COVID-19 therapeutic
On Oct. 21, 2021, Ligand Pharmaceuticals announced the signing of a collaboration agreement granting China Resources Double-Crane Pharmaceutical…
U.S. CDC Advisory Committee unanimously recommended Johnson & Johnson COVID-19 vaccine as booster for all eligible individuals
On Oct. 21, 2021, Johnson & Johnson announced that the U.S. Centers for Disease Control and Prevention (CDC)…
Pfizer and BioNTech announced phase 3 trial data showing high efficacy of booster dose of COVID-19 vaccine
On Oct. 21, 2021, Pfizer and BioNTech announced topline results from a Phase 3 randomized, controlled trial evaluating…
INOVIO announced MOU with Colombia for protecting against COVID-19 and broader health initiatives
On Oct. 21, 2021, Inovio Pharma announced the signing of a non-binding memorandum of understanding with Colombia’s Ministry…
NIH launched program to map a rare type of non-dividing cells implicated in human health and disease
On Oct. 18, 2021, the National Institutes of Health launched a program to study a rare type of…
Moderna announced FDA authorization of booster dose of COVID-19 vaccine in the U.S.
On Oct. 20, 2021, Moderna announced that the U.S. Food and Drug Administration (FDA) had authorized for emergency…
Johnson & Johnson COVID-19 vaccine booster shot authorized for Emergency Use by U.S. FDA
On Oct. 20, 2021, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) had issued Emergency…
Quest Diagnostics provided K-12 School COVID-19 testing with Ginkgo Bioworks to support safer classrooms in Texas
On Oct. 20, 2021, Quest Diagnostics announced it had formed an agreement with the Texas Department of State…
NYU Langone Health’s Groundbreaking Transplant Offers Hope amid Organ Shortages
On Oct. 19, 2021, the first investigational transplant of a genetically engineered, nonhuman kidney to a human body…
Study found that for the unvaccinated, reinfection by COVID-19 was likely
On Oct. 19, 2021, National Science Foundation funded scientists at the Yale School of Public Health and the…
Largest ever global study of tuberculosis identified genetic causes of drug resistance
On Oct. 19 , 2021, researchers at the University of Oxford, using cutting-edge genomic sequencing techniques, announced they…
Subcutaneous Interferon does not improve outcomes for hospitalized adults with COVID-19
On Oct. 18, 2021, a NIAID sponsored clinical trial found that treatment with the immunomodulator interferon beta-1a plus…
COVID-19 vaccine developed by Valneva using Dynavax’s CpG 1018 adjuvant met co-primary endpoints in phase 3 trial
On Oct. 18, 2021, Dynavax Technologies announced that Valneva reported positive topline results from the Phase 3 pivotal…